ANZUP AT ASCO GU 2020

ANZUP was fortunate to have five trials in progress at ASCO GU in San Francisco in February.

Congratulations to everyone involved in these important ANZUP studies.

PCR-MIB (ANZUP 1502) Study Chair Andrew Weickhardt presented the poster on pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: a planned interim analysis of safety and efficacy of the PCRMIB phase II clinical trial.

ANZUP Fellow Shahlini Subramaniam presented the P3BEP (ANZUP 1302) poster: an international randomised phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).

ANZUP Fellow Elizabeth Liow presented the BCGMM (ANZUP 1301) poster: adding mitomycin to Bacillus CalmetteGuérin as adjuvant intravesical therapy for high-risk, non muscle-invasive urothelial bladder cancer.

ANZUP AT ASCO GU 2020

DASL-HiCaP (ANZUP 1801)

Study Co-Chair Tamim Niazi presented the DASLHiCaP poster: the impact of darolutamide on standard therapy for localised very highrisk cancer of the prostate – A randomised phase III doubleblind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localised prostate cancer.

Study Chair Craig Gedye presented the UNISoN (ANZUP 1602) poster: nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.

As ANZUP fellow, I truly valued the opportunity of being involved with ANZUP’s UNISoN trial. UNISoN is an important trial that focuses on patients with non-clear cell kidney cancer, and may expand the treatment armamentarium for a group of patients who do not have access to many effective treatment options. I for one eagerly anticipate the results from the UNISoN trial.